Meeting
2013 ASCO Annual Meeting
Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.
Authors
Peter Fox
Westmead Hospital, Sydney, Australia
Peter Fox , Bo Gao , Bavanthi Balakrishnar , Alexander M Menzies , Shang Heng Yeap , Sayed Sahanawaz Ali , Val Gebski , Pamela Provan , Sally Coulter , Christopher Liddle , Rina Hui , Richard Kefford , Jodi Lynch , Nicholas Wilcken , Rosemary L Balleine , Howard Gurney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01075802
Citation
J Clin Oncol 31, 2013 (suppl; abstr 543)
DOI
10.1200/jco.2013.31.15_suppl.543
Abstract #
543
Poster Bd #
1F
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
First Author: Bavanthi Balakrishnar
Poster
2020 ASCO Virtual Scientific Program
Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease.
First Author: Andrea De Censi
Poster
2018 ASCO Annual Meeting
A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.
First Author: Anabel Beatriz Sanchez-Spitman
Poster
2018 ASCO Annual Meeting
A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.
First Author: Toshimi Takano